Jump to content

Vernakalant

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Carlo Banez (talk | contribs) at 19:43, 15 March 2008 (←Created page with ''''Vernakalant''', (codenamed RSD1235, proposed tradename Kynapid) is an investigational drug under regulatory review for the acute conversion ...'). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)

Vernakalant, (codenamed RSD1235, proposed tradename Kynapid) is an investigational drug under regulatory review for the acute conversion of atrial fibrillation.

It is being developed by Cardiome Pharma Corp.

On December 11, 2007, the Cardiovascular and Renal Drugs Advisory Committee of the US Food and Drug Administration voted to recommend the approval of vernakalant.[1]

An oral formulation is currently undergoing Phase II clinical studies.

Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

  1. ^ "Drugs.com, FDA Advisory Committee Recommends Approval of Kynapid for Acute Atrial Fibrillation". Retrieved 2008-03-15.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Vernakalant&oldid=198467691"